SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kanika Gupta, Mona Yezdani, Tiffany Sotelo, Jeanny B Aragon-Ching, A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia, Expert Opinion on Investigational Drugs, 2015, 1

    CrossRef

  2. 2
    Shengkun Sun, Yufeng Bai, Hongmei Yang, Hong-wei Yang, Investigation on lower urinary tract symptoms (LUTS) in elderly patients with prostate cancer (PC) received endocrine therapy, Archives of Gerontology and Geriatrics, 2015, 60, 3, 535

    CrossRef

  3. 3
    Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven, Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study, Prostate Cancer, 2015, 2015, 1

    CrossRef

  4. 4
    Toshikazu Takeda, Akira Miyajima, Gou Kaneko, Eiji Kikuchi, Ken Nakagawa, Mototsugu Oya, Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates, Asian Journal of Endoscopic Surgery, 2014, 7, 2
  5. 5
    Mack Roach, Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer, Cancer, 2014, 120, 11
  6. 6
    Natalie J. Carter, Susan J. Keam, Degarelix: A Review of Its Use in Patients with Prostate Cancer, Drugs, 2014, 74, 6, 699

    CrossRef

  7. 7
    Laurence Klotz, Kurt Miller, E. David Crawford, Neal Shore, Bertrand Tombal, Cathrina Karup, Anders Malmberg, Bo-Eric Persson, Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists, European Urology, 2014, 66, 6, 1101

    CrossRef

  8. 8
    Michael T. Bowen, A worldwide yearly survey of new data in adverse drug reactions, 2014,

    CrossRef

  9. 9
    Rajnish Kumar, Priyanka Malla, Manoj Kumar, Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia, Expert Opinion on Drug Discovery, 2013, 8, 8, 1013

    CrossRef

  10. 10
    Patrizia Limonta, Marilena Manea, Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies, Cancer Treatment Reviews, 2013, 39, 6, 647

    CrossRef

  11. 11
    M. Mason, X. Maldonado Pijoan, C. Steidle, S. Guerif, T. Wiegel, E. van der Meulen, P.B.F. Bergqvist, V. Khoo, Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide, Clinical Oncology, 2013, 25, 3, 190

    CrossRef

  12. 12
    Ferenc G. Rick, Norman L. Block, Andrew V. Schally, Re: Editorial Comment on LHRH Antagonist Cetrorelix Reduces Prostate Size and Gene Expression of Proinflammatory Cytokines and Growth Factors in a Rat Model of Benign Prostatic Hyperplasia (Prostate 2011; 71: 736–747), The Journal of Urology, 2013, 189, 4, 1604

    CrossRef

  13. 13
    F. Schröder, E.D. Crawford, K. Axcrona, H. Payne, T.E. Keane, Androgen deprivation therapy: past, present and future, BJU International, 2012, 109,